Q2 2026 CVS Health Corp Earnings Call Transcript
Key Points
- CVS Health Corp (CVS) delivered strong second-quarter results with all operating segments growing earnings, generating adjusted EPS of $2.58, a 40% increase year-over-year.
- The company raised its full-year 2026 adjusted EPS guidance by $0.60 to a range of $7.90-$8.10 and increased its cash flow from operations outlook by $2 billion to at least $11.5 billion.
- Aetna's margin recovery is progressing well, with over $2 billion in year-over-year adjusted operating income improvement in the first half of 2026, driven by strong medical cost management and disciplined pricing.
- The Pharmacy and Consumer Wellness segment delivered an exceptional quarter, with same-store prescription volumes up 7% and adjusted operating income up over 10%, driven by core pharmacy strength and contributions from the Rite Aid transaction.
- CVS Health Corp (CVS) is strategically positioning itself in the GLP-1 market through partnerships with Eli Lilly and Novo Nordisk, offering affordable cash-pay options and leveraging its MinuteClinic and pharmacy network to capture growth.
- The company is making significant progress in its technology and AI initiatives, including the launch of its Health 100 platform and AI-powered assistant HIO, which are expected to drive efficiencies and enhance the consumer experience.
- CVS Health Corp (CVS) expects a headwind in 2027 from continued pressure in its 340B business due to manufacturer restrictions and the dynamic environment for the program.
- The company anticipates membership declines in Caremark next year due to a deliberate approach to client renewals and the selling season, as well as product actions and market exits by some health plan customers.
- The transition to net cost price models in the PBM industry, accelerated by recent legislation and regulatory developments, is creating near-term earnings pressure and uncertainty.
- The company is facing challenges from the independent dispute resolution process under the No Surprises Act, which is being abused by a small group of players and is frustrating self-funded employers.
- CVS Health Corp (CVS) is experiencing pressure from pharmacy reimbursement and regulatory-related price reductions on certain drugs, which partially offset revenue growth in its Pharmacy and Consumer Wellness segment.
- The company's 2027 outlook of at least $8.44 in adjusted EPS assumes only offsetting dilution from share repurchases, with no additional capital deployment, limiting potential upside from buybacks.
Hello and welcome to CVS Health second quarter 2026 earnings call. We ask that you please hold all questions until the end of the prepared remarks, at which time you'll be given instructions for the question-and-answer session.
As a reminder, this conference is being recorded today.
If you have any objections, please disconnect at this time.
I would now like to pass the call over to Larry McGrath. Larry, please proceed.
Good morning, and welcome to the CVS Health second quarter 2026 earnings call and webcast.
I'm Larry McGrath, Executive Vice President of Capital Markets at CVS Health.
I'm joined this morning by David Joyner, Chair and Chief Executive Officer and Brian Newman, Chief Financial Officer.
Following our prepared remarks, we'll host a question-and-answer session that will include additional members of the leadership team.
Our press release and slide presentation have been posted to our website, along
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
